SK55997A3 - Small particle formation - Google Patents

Small particle formation Download PDF

Info

Publication number: SK55997A3
Authority: SK; Slovakia
Prior art keywords: polymer; solvent; organic mixture; mixture; solution
Prior art date: 1994-11-09

Application number

SK559-97A

Other languages

English (en)

Slovak (sk)

Inventor

Sylvan Frank

Jan-Erik Lofroth

Levon Bostanian

Original Assignee

Univ Ohio State Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-09

Filing date

1995-11-03

Publication date

1998-01-14

1995-11-03 Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found

1998-01-14 Publication of SK55997A3 publication Critical patent/SK55997A3/sk

Links

239000002245 particle Substances 0.000 title claims abstract description 25
230000015572 biosynthetic process Effects 0.000 title abstract description 5
229920000642 polymer Polymers 0.000 claims abstract description 41
238000000034 method Methods 0.000 claims abstract description 19
150000001875 compounds Chemical class 0.000 claims abstract description 9
OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical class CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims abstract description 8
239000000203 mixture Substances 0.000 claims description 31
239000002904 solvent Substances 0.000 claims description 26
239000000243 solution Substances 0.000 claims description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
239000002244 precipitate Substances 0.000 claims description 8
239000000693 micelle Substances 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 5
239000003125 aqueous solvent Substances 0.000 claims description 4
150000002632 lipids Chemical class 0.000 claims description 4
239000007864 aqueous solution Substances 0.000 claims description 3
238000005119 centrifugation Methods 0.000 claims description 3
230000002209 hydrophobic effect Effects 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
239000003792 electrolyte Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 1
150000002894 organic compounds Chemical class 0.000 abstract description 3
239000012736 aqueous medium Substances 0.000 abstract description 2
230000001376 precipitating effect Effects 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
-1 dexamethasone steroid compounds Chemical class 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
239000001267 polyvinylpyrrolidone Substances 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
238000001556 precipitation Methods 0.000 description 5
235000019333 sodium laurylsulphate Nutrition 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
238000003756 stirring Methods 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000000084 colloidal system Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000003993 interaction Effects 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229910000160 potassium phosphate Inorganic materials 0.000 description 3
235000011009 potassium phosphates Nutrition 0.000 description 3
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 3
229960003912 probucol Drugs 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000007423 decrease Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
241000220479 Acacia Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010014476 Elevated cholesterol Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
239000008406 cosmetic ingredient Substances 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000008151 electrolyte solution Substances 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000005189 flocculation Methods 0.000 description 1
230000016615 flocculation Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229920006158 high molecular weight polymer Polymers 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
229920000831 ionic polymer Polymers 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
239000000047 product Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000001223 reverse osmosis Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
229960004306 sulfadiazine Drugs 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Dispersion Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
Saccharide Compounds (AREA)
Heat Sensitive Colour Forming Recording (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Surgical Instruments (AREA)
Manufacturing Of Micro-Capsules (AREA)
Confectionery (AREA)
Soft Magnetic Materials (AREA)
Steroid Compounds (AREA)

SK559-97A 1994-11-09 1995-11-03 Small particle formation SK55997A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9403846A SE9403846D0 (sv)	1994-11-09	1994-11-09	Small particle formation
PCT/SE1995/001302 WO1996014833A1 (en)	1994-11-09	1995-11-03	Small particle formation

Publications (1)

Publication Number	Publication Date
SK55997A3 true SK55997A3 (en)	1998-01-14

Family

ID=20395907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK559-97A SK55997A3 (en)	1994-11-09	1995-11-03	Small particle formation

Country Status (27)

Country	Link
US (1)	US5780062A (is)
EP (1)	EP0788350B1 (is)
JP (1)	JP4098827B2 (is)
KR (1)	KR970706799A (is)
CN (1)	CN1165478A (is)
AT (1)	ATE213625T1 (is)
AU (1)	AU700644B2 (is)
BR (1)	BR9509720A (is)
CA (1)	CA2203512A1 (is)
CZ (1)	CZ129597A3 (is)
DE (1)	DE69525639T2 (is)
DK (1)	DK0788350T3 (is)
EE (1)	EE9700214A (is)
ES (1)	ES2173204T3 (is)
FI (1)	FI118511B (is)
HU (1)	HUT77629A (is)
IL (1)	IL115878A0 (is)
IS (1)	IS4467A (is)
NO (1)	NO971986D0 (is)
NZ (1)	NZ295497A (is)
PL (1)	PL320425A1 (is)
PT (1)	PT788350E (is)
SE (1)	SE9403846D0 (is)
SK (1)	SK55997A3 (is)
TR (1)	TR199501400A2 (is)
WO (1)	WO1996014833A1 (is)
ZA (1)	ZA959386B (is)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2736550B1 (fr)	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US6143211A (en) *	1995-07-21	2000-11-07	Brown University Foundation	Process for preparing microparticles through phase inversion phenomena
US7029700B2 (en) *	2000-01-14	2006-04-18	Brown University Research Foundation	Micronized freeze-dried particles
WO2001052818A1 (en)	2000-01-19	2001-07-26	Pharmaceutical Discovery Corporation	Dry powder formulations of antihistamine for nasal administration
US9700866B2 (en)	2000-12-22	2017-07-11	Baxter International Inc.	Surfactant systems for delivery of organic compounds
AU2002249836B2 (en) *	2000-12-22	2006-12-14	Baxter International Inc.	Method for preparing submicron particle suspensions
US20040022862A1 (en) *	2000-12-22	2004-02-05	Kipp James E.	Method for preparing small particles
US20030096013A1 (en) *	2000-12-22	2003-05-22	Jane Werling	Preparation of submicron sized particles with polymorph control
US6884436B2 (en) *	2000-12-22	2005-04-26	Baxter International Inc.	Method for preparing submicron particle suspensions
US6977085B2 (en)	2000-12-22	2005-12-20	Baxter International Inc.	Method for preparing submicron suspensions with polymorph control
US8067032B2 (en)	2000-12-22	2011-11-29	Baxter International Inc.	Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) *	2000-12-22	2007-03-20	Baxter International Inc.	Polymorphic form of itraconazole
US20050048126A1 (en) *	2000-12-22	2005-03-03	Barrett Rabinow	Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6951656B2 (en)	2000-12-22	2005-10-04	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) *	2000-12-22	2004-12-23	Mahesh Chaubal	Process for production of essentially solvent-free small particles
US6607784B2 (en)	2000-12-22	2003-08-19	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US6623761B2 (en)	2000-12-22	2003-09-23	Hassan Emadeldin M.	Method of making nanoparticles of substantially water insoluble materials
DE10117049A1 (de) *	2001-04-05	2002-10-17	Novartis Ag	Zusammensetzung
MXPA03011935A (es) *	2001-06-22	2004-03-26	Pfizer Prod Inc	Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
EP1416917B1 (en) *	2001-08-06	2007-06-27	AstraZeneca AB	Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct)
JP2004537401A (ja) *	2001-08-08	2004-12-16	ブラウンユニバーシティリサーチファウンデーション	疎水性薬物の微粉砕方法
US20060003012A9 (en)	2001-09-26	2006-01-05	Sean Brynjelsen	Preparation of submicron solid particle suspensions by sonication of multiphase systems
AU2002337692B2 (en)	2001-09-26	2007-09-13	Baxter International Inc.	Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en)	2001-10-19	2006-09-26	Baxter International Inc.	Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0216700D0 (en) *	2002-07-18	2002-08-28	Astrazeneca Ab	Process
US20040028747A1 (en) *	2002-08-06	2004-02-12	Tucker Christopher J.	Crystalline drug particles prepared using a controlled precipitation process
GB0230087D0 (en) *	2002-12-24	2003-01-29	Astrazeneca Ab	Therapeutic agents
GB0230088D0 (en) *	2002-12-24	2003-01-29	Astrazeneca Ab	Therapeutic agents
GB0302671D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
GB0302672D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
GB0302673D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
US7511079B2 (en) *	2003-03-24	2009-03-31	Baxter International Inc.	Methods and apparatuses for the comminution and stabilization of small particles
CN1791386A (zh) *	2003-05-19	2006-06-21	巴克斯特国际公司	抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂
GB0314057D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
JP2006527770A (ja) *	2003-06-18	2006-12-07	アストラゼネカアクチボラグ	Ｃｂ１モジュレーターとしての２−置換５，６−ジアリール−ピラジン誘導体
GB0314261D0 (en) *	2003-06-19	2003-07-23	Astrazeneca Ab	Therapeutic agents
WO2004112747A2 (en) *	2003-06-24	2004-12-29	Baxter International Inc.	Specific delivery of drugs to the brain
US8986736B2 (en) *	2003-06-24	2015-03-24	Baxter International Inc.	Method for delivering particulate drugs to tissues
CA2539494C (en)	2003-09-22	2011-12-06	Baxter International Inc.	High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
US20050181059A1 (en) *	2003-09-30	2005-08-18	Spherics, Inc.	Nanoparticulate therapeutic biologically active agents
DE10351087A1 (de) *	2003-10-31	2005-05-25	Bayer Technology Services Gmbh	Feste Wirkstoff-Formulierung
RU2006130958A (ru) *	2004-01-29	2008-03-10	Бакстер Интернэшнл Инк. (Us)	Наносуспензии антиретровирусных агентов для улучшенной доставки в центральную нервную систему
EP1711163A2 (en) *	2004-02-05	2006-10-18	Baxter International Inc.	Dispersions prepared by use of self-stabilizing agents
CA2565972A1 (en) *	2004-06-15	2005-12-29	Baxter International Inc.	Ex-vivo application of solid microparticulate therapeutic agents
US20080171687A1 (en) *	2004-09-16	2008-07-17	Abraxis Bioscience, Inc.	Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
US8703204B2 (en)	2007-05-03	2014-04-22	Bend Research, Inc.	Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) *	2007-05-03	2012-11-13	Bend Research, Inc.	Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8530463B2 (en) *	2007-05-07	2013-09-10	Hale Biopharma Ventures Llc	Multimodal particulate formulations
EP2152274A4 (en) *	2007-05-07	2010-07-21	Questor Pharmaceuticals Inc	NASAL ADMINISTRATION OF BENZODIAZEPINES
US8426467B2 (en)	2007-05-22	2013-04-23	Baxter International Inc.	Colored esmolol concentrate
US8722736B2 (en)	2007-05-22	2014-05-13	Baxter International Inc.	Multi-dose concentrate esmolol with benzyl alcohol
EP2162120B1 (en)	2007-06-04	2016-05-04	Bend Research, Inc	Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en)	2007-06-04	2008-12-11	Pfizer Products Inc.	Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US8101274B2 (en) *	2007-06-11	2012-01-24	Spedden Richard H	Solid state membranes with surface-embedded glycosylated amphiphilic molecules and micelles formed therefrom
GB0714223D0 (en) *	2007-07-20	2007-08-29	Fujifilm Mfg Europe Bv	Preparation of fine particles
EP2240162A4 (en)	2007-12-06	2013-10-09	Bend Res Inc	NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
EP2231169B1 (en)	2007-12-06	2016-05-04	Bend Research, Inc.	Pharmaceutical compositions comprising nanoparticles and a resuspending material
CN101965195A (zh)	2008-03-05	2011-02-02	巴克斯特国际公司	用于药物投送的组合物和方法
JP5613657B2 (ja)	2008-03-28	2014-10-29	ヘイルバイオファーマベンチャーズ，エルエルシー	ベンゾジアゼピン組成物の投与
CN101278921B (zh) *	2008-06-03	2010-06-09	海南百那医药发展有限公司	盐酸托烷司琼微囊及其注射剂生产方法
US20100151037A1 (en) *	2008-08-07	2010-06-17	Yivan Jiang	Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
US8889168B2 (en)	2008-08-07	2014-11-18	Bioactive Surgical Inc.	Stem cell capture and immobilization coatings for medical devices and implants
US10952965B2 (en) *	2009-05-15	2021-03-23	Baxter International Inc.	Compositions and methods for drug delivery
CN102784103A (zh) *	2011-05-16	2012-11-21	中国科学院上海药物研究所	一种通过混合胶束技术制备的普罗布考纳米混悬液及其制备方法
US20140199397A1 (en) *	2011-06-10	2014-07-17	Daniel Levin	Benzoyl Peroxide Microparticle Process
DK3415139T3 (da)	2011-06-14	2022-06-20	Neurelis Inc	Administration af benzodiazepin
WO2015071841A1 (en)	2013-11-12	2015-05-21	Druggability Technologies Holdings Limited	Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2016181406A1 (en) *	2015-05-08	2016-11-17	Davuluri Ramamohan Rao	Improved process for the preparation of aripiprazole with reduced particle size
US12599611B2 (en)	2021-06-10	2026-04-14	Neurelis, Inc.	Methods and compositions for treating seizure disorders in pediatric patients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3013839A1 (de) *	1979-04-13	1980-10-30	Freunt Ind Co Ltd	Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1282405C (en) *	1984-05-21	1991-04-02	Michael R. Violante	Method for making uniformly sized particles from water-insoluble organic compounds
US4826689A (en) *	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) *	1984-12-21	1986-08-19	The Ohio State University Research Foundation	Small particle formation and encapsulation
JPH0249720A (ja) *	1988-05-18	1990-02-20	Mitsubishi Kasei Corp	難溶性薬剤組成物
SE464743B (sv) *	1989-06-21	1991-06-10	Ytkemiska Inst	Foerfarande foer framstaellning av laekemedelspartiklar
IT1243390B (it) *	1990-11-22	1994-06-10	Vectorpharma Int	Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.

1994
- 1994-11-09 SE SE9403846A patent/SE9403846D0/xx unknown
1995
- 1995-11-03 CN CN95196084A patent/CN1165478A/zh active Pending
- 1995-11-03 AT AT95938091T patent/ATE213625T1/de not_active IP Right Cessation
- 1995-11-03 KR KR1019970703072A patent/KR970706799A/ko not_active Withdrawn
- 1995-11-03 DK DK95938091T patent/DK0788350T3/da active
- 1995-11-03 BR BR9509720A patent/BR9509720A/pt unknown
- 1995-11-03 CA CA002203512A patent/CA2203512A1/en not_active Abandoned
- 1995-11-03 DE DE69525639T patent/DE69525639T2/de not_active Expired - Lifetime
- 1995-11-03 WO PCT/SE1995/001302 patent/WO1996014833A1/en not_active Ceased
- 1995-11-03 CZ CZ971295A patent/CZ129597A3/cs unknown
- 1995-11-03 PL PL95320425A patent/PL320425A1/xx unknown
- 1995-11-03 EE EE9700214A patent/EE9700214A/xx unknown
- 1995-11-03 NZ NZ295497A patent/NZ295497A/en unknown
- 1995-11-03 ES ES95938091T patent/ES2173204T3/es not_active Expired - Lifetime
- 1995-11-03 SK SK559-97A patent/SK55997A3/sk unknown
- 1995-11-03 PT PT95938091T patent/PT788350E/pt unknown
- 1995-11-03 JP JP51597096A patent/JP4098827B2/ja not_active Expired - Fee Related
- 1995-11-03 US US08/553,460 patent/US5780062A/en not_active Expired - Lifetime
- 1995-11-03 HU HU9800181A patent/HUT77629A/hu unknown
- 1995-11-03 AU AU38851/95A patent/AU700644B2/en not_active Ceased
- 1995-11-03 EP EP95938091A patent/EP0788350B1/en not_active Expired - Lifetime
- 1995-11-06 ZA ZA959386A patent/ZA959386B/xx unknown
- 1995-11-06 IL IL11587895A patent/IL115878A0/xx unknown
- 1995-11-09 TR TR95/01400A patent/TR199501400A2/xx unknown
1997
- 1997-04-21 IS IS4467A patent/IS4467A/is unknown
- 1997-04-29 NO NO971986A patent/NO971986D0/no unknown
- 1997-05-07 FI FI971947A patent/FI118511B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
BR9509720A (pt)	1997-10-21
HUT77629A (hu)	1998-06-29
SE9403846D0 (sv)	1994-11-09
US5780062A (en)	1998-07-14
EE9700214A (et)	1998-04-15
WO1996014833A1 (en)	1996-05-23
ES2173204T3 (es)	2002-10-16
FI971947A0 (fi)	1997-05-07
NO971986L (no)	1997-04-29
EP0788350B1 (en)	2002-02-27
CZ129597A3 (en)	1997-12-17
DE69525639T2 (de)	2002-08-29
DK0788350T3 (da)	2002-04-29
IL115878A0 (en)	1996-01-31
ATE213625T1 (de)	2002-03-15
NO971986D0 (no)	1997-04-29
ZA959386B (en)	1996-05-09
DE69525639D1 (de)	2002-04-04
KR970706799A (ko)	1997-12-01
FI971947L (fi)	1997-05-07
TR199501400A2 (tr)	1996-06-21
AU700644B2 (en)	1999-01-14
CA2203512A1 (en)	1996-05-23
PT788350E (pt)	2002-07-31
PL320425A1 (en)	1997-09-29
JP4098827B2 (ja)	2008-06-11
JPH10508840A (ja)	1998-09-02
IS4467A (is)	1997-04-21
FI118511B (fi)	2007-12-14
NZ295497A (en)	1998-05-27
CN1165478A (zh)	1997-11-19
EP0788350A1 (en)	1997-08-13
AU3885195A (en)	1996-06-06

Publication	Publication Date	Title
JP4098827B2 (ja)	2008-06-11	微細粒子の形成
RU2186562C2 (ru)	2002-08-10	Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US5622938A (en)	1997-04-22	Sugar base surfactant for nanocrystals
Bodmeier et al.	1990	Indomethacin polymeric nanosuspensions prepared by microfujidization
US4997454A (en)	1991-03-05	Method for making uniformly-sized particles from insoluble compounds
AU696400B2 (en)	1998-09-10	Process for coating droplets or nanometric particles
EP0544657A1 (en)	1993-06-09	Method for making uniformly-sized particles from insoluble compounds
WO1996022766A1 (en)	1996-08-01	Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
NO303668B1 (no)	1998-08-17	Overflatemodifiserte legemiddel-nanopartikler, fremgangsmÕte for deres fremstilling samt dispersjon inneholdende slike partikler
JPH07165562A (ja)	1995-06-27	表面を修飾された抗癌性ナノ粒子
JPH0657005A (ja)	1994-03-01	ナノカプセルあるいはナノ粒子の分散コロイダル系の連続製造方法
Helttunen et al.	2016	Solid lipid nanoparticles from amphiphilic calixpyrroles
CA2460649A1 (en)	2003-03-27	Novel calixarene based dispersible colloidal systems in the form of nanoparticles
WO2012047691A2 (en)	2012-04-12	Method of modifying dissolution rate of particles by addition of hydrophobic nanoparticles
CN104084088A (zh)	2014-10-08	支化型双亲聚合物自组装胶束作为乳化剂的应用
Encina et al.	1992	Phase diagram studies of microcapsule formation using hydroxypropyl methylcellulose phthalate
US9700509B2 (en)	2017-07-11	Solutions of lipophilic substances, especially medicinal solutions
EP1539110A1 (en)	2005-06-15	Crystalline drug particles prepared using a controlled precipitation process
Kawamata et al.	2019	Fabrication and Surface-Modification of Silica/Gadolinium Compound/Silica Core-Shell Nanoparticles Discovered by Transmission Electron Microscopy
Uda et al.	2009	Photochemically triggered transfer of bovine serum albumin by reverse micelle containing a Malachite Green leuconitrile derivative
Skandalis et al.	2018	polymers MDPI
CN119081162A (zh)	2024-12-06	Pickering乳液聚合制备两性太子参多糖-姜黄素纳米颗粒的方法
HK1017807B (en)	2001-08-31	Process for coating droplets or nanometric particles
US20040213834A1 (en)	2004-10-28	Pharmacological preparation made from a nanopatriculate mesomorphous polyelectrolyte lipid complex and at least one active ingredient
Ghareeb et al.	0	Effects of formulation variables on the Candesartan cilexitil nanoparticles properties using poloxamer 188